Time trends and survival after operations for primary lung cancer from 1976 through 1990

Wada, Hiromi; Tanaka, Fumihiro; Yanagihara, Kazuhiro; Ariyasu, Tetsuya; Fukuse, Tatsuo; Yokomise, Hiroyasu; Inui, Kentaro; Mizuno, Hiroshi; Ike, Osamu; Hitomï, Shigeki

doi:10.1016/s0022-5223(96)70261-1

Cited by 48 publications

(26 citation statements)

References 10 publications

(1 reference statement)

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…As postoperative adjuvant therapy, 13 patients received intravenous chemotherapy, seven received oral administration of UFT, a 5-fluorouracil derivative chemotherapeutic agent, and one received both; the other 97 patients received no therapy postoperatively. Complete tumor resection was considered to have been achieved when no microscopic cancer was identified in either the margin of resection of the tumor or the highest mediastinal lymph nodes [24]. Pathologic stage was determined according to the tumor-node metastasis (TNM) classification as revised in 1997 [2].…”

Section: Introductionmentioning

confidence: 99%

Clinical significance of caspase-3 expression in pathologic-stage I, nonsmall-cell lung cancer

et al. 2001

Self Cite

View full text Add to dashboard Cite

SUMMARY Caspase-3 is a cysteine protease that plays an important role in the process of apoptotic cell death. Whereas many studies on the clinical significance of apoptosis in the therapy of malignant tumors have been reported, little has been studied clinically on caspase-3. In the present study, the clinical significance of caspase-3 expression in resected nonsmall-cell lung cancer (NSCLC) and its correlation with incidence of apoptosis were examined. A total of 118 consecutive patients who had undergone complete resection for pathologic Stage I NSCLC were retrospectively reviewed. Caspase-3 expression was examined immunohistochemically using a polyclonal antibody that recognized uncleaved caspase-3. The 5-year survival rate for patients with strong expression of caspase-3 (66.6%) was significantly lower than that for patients with weak expression (82.1%, P ‫؍‬ 0.021). Expression of caspase-3 was not correlated with incidence of apoptosis, proliferative activity, or p53 status. Multivariate analysis confirmed that strong expression of caspase-3 was a significant factor to predict poor prognosis. These results suggest that enhanced expression of "uncleaved" caspase-3, that is, inactivated caspase-3, was correlated with poor prognosis in resected NSCLC.

show abstract

Section: Introductionmentioning

confidence: 99%

Clinical significance of caspase-3 expression in pathologic-stage I, nonsmall-cell lung cancer

et al. 2001

Self Cite

View full text Add to dashboard Cite

show abstract

“…radical surgery, has remained the same, but the surgical techniques and postoperative treatments have improved. Clinical studies addressing the effects of chemotherapy and combination therapy, especially in small cell carcinoma and stage III disease have suggested that they prolong survival [3][4][5]. Many of these studies have, however, been conducted in centres with a particular interest in chemotherapy and in groups of patients with strictly defined inclusion criteria.…”

mentioning

confidence: 99%

Prospective population-based study on the survival of patients with lung cancer

Mäkitaro¹,

Pääkkö²,

Huhti³

et al. 2002

European Respiratory Journal

View full text Add to dashboard Cite

Prospective population-based study on the survival of patients with lung cancer. R. Mäkitaro, P. Pääkko, E. Huhti, R. Bloigu, V.L. Kinnula. #ERS Journals Ltd 2002. ABSTRACT: The purpose of this study was to evaluate the change, over 20 yrs, in the survival of lung cancer patients in a population-based study.Information on all patients with lung cancer in a defined geographical area during 1990-1992 (n=602) was prospectively gathered. The survival of these patients was assessed and also compared with the results of a similar study in the same area during the years 1968-1971 (n=446).The 5-yr survival had improved during 20 yrs from 4% to 12%. The 5-yr survival of the patients with squamous cell carcinoma had increased from 6% to 16%, and adenocarcinoma from 4% to 19%, whereas the survival of small cell carcinoma had remained the same (2% and 3%, respectively). Even though the recent patients were older than those of the earlier series the proportion of surgically treated patients had remained the same (16% and 20%), but the 5-yr survival of patients who had been operated on had increased significantly from 23% to 48%. The differences in survival in the second cohort (1990)(1991)(1992) between histological types (Chi-squared logrank=59.2), tumour, node, metastasis stages (Chi-squared logrank=199.6), symptomatic stages (Chi-squared logrank=120, pv0.001) and treatment (Chi-squared logrank=277) were significant.Based on this study the independent prognostic factors for better survival of lung cancer patients are tumour, node, metastasis stages I and II, surgical treatment and Feinstein9s symptomatic stages I and II.

show abstract

“…They found that the group who had received UFT showed a significantly better prognosis than the group who had not. However, in these two reports, 26,27 it was not clear why UFT was effective when used for postoperative adjuvant chemotherapy in patients with NSCLC. Thus, within the limits of conjecture, it is possible that UFT targets the micro-metastatic lesions of lymph nodes 28 in patients with p-N0 NSCLC.…”

Section: Discussionmentioning

confidence: 98%

“…Wada et al 27 examined the 5-year survival rate of patients with p-N0 NSCLC to whom UFT was administered as an additional postoperative adjuvant chemotherapy after complete resection and initial postoperative adjuvant chemotherapy with PVM (cisplatin ϩ vindesine ϩ mitomycin C). They found that the group who had received UFT showed a significantly better prognosis than the group who had not.…”

Section: Discussionmentioning

confidence: 99%

Drug concentration in lymph nodes after preoperative administration of UFT (a blend of Tegafur and uracil) for non-small-cell lung cancer

et al. 2000

View full text Add to dashboard Cite

Background. UFT a blend of uracil and Tegafur (1-[2-tetrahydrofuryl]-5 fluorouracil), molar ratio, 4 : 1 is an antitumor agent for oral administration that is presumed to maintain the concentration of 5-fluorouracil (5-FU) in tumor tissue. The concentration of 5-FU achieved with UFT in lymph node metastases has, however, not yet been examined; in this study we aimed to clarify the transfer of 5-FU to lymph node metastases in patients treated with UFT. Methods. The subjects were 21 patients with primary nonsmall-cell lung cancer (NSCLC). Tegafur (600 mg per day), in the form of UFT-E (UFT enteric-coated granules), was administered for 7 days prior to surgery. At the time of lobectomy and lymphadenectomy, 0.3-g tissue specimens were collected from the primary lung tumor, normal lung, lymph node metastases, and normal lymph nodes. The concentrations of Tegafur and 5-FU in each sample were measured. Results. The concentration of 5-FU in lymph node metastases was 63.5 Ϯ 11.6 ng/g, which was greater than the minimum effective tissue concentration (50 ng/g), and was significantly higher than the concentration in normal lymph nodes (P ϭ 0.0053). The concentration of 5-FU in the tumor (50.7 Ϯ 9.7 ng/g) was also greater than the minimum effective tissue concentration, and was significantly higher than the concentration in normal lung tissue (P ϭ 0.0193). No serious side effects were observed during the administration of UFT-E. Conclusions. We concluded that UFT would be useful as a postoperative adjuvant chemotherapeutic agent in patients with NSCLC and lymph node metastases, considering the excellent transfer of 5-FU to lymph node metastases during treatment with UFT.

show abstract

Time trends and survival after operations for primary lung cancer from 1976 through 1990

Cited by 48 publications

References 10 publications

Clinical significance of caspase-3 expression in pathologic-stage I, nonsmall-cell lung cancer

Clinical significance of caspase-3 expression in pathologic-stage I, nonsmall-cell lung cancer

Prospective population-based study on the survival of patients with lung cancer

Drug concentration in lymph nodes after preoperative administration of UFT (a blend of Tegafur and uracil) for non-small-cell lung cancer

Contact Info

Product

Resources

About